Jiangsu wuzhong(600200)2024-01-23 08:21Group 1: Product Overview - AestheFill is an imported aesthetic injection product developed by REGEN Biotech, Inc., first approved in South Korea in 2014 and now sold in over 60 countries [3] - In Taiwan, AestheFill holds nearly 30% market share in the aesthetic regenerative injection market, ranking first [4] - The product utilizes PDLLA microspheres, which enhance collagen regeneration and allow for personalized treatment plans based on tissue characteristics [4] Group 2: Sales Strategy - The marketing team for AestheFill consists of approximately 20 members, with plans for further expansion [4] - The primary sales model will be self-operated to facilitate the launch of other products and maintain price control [5] - AestheFill's initial promotion will focus on nasolabial folds, with extensive training for doctors planned [6] Group 3: Market Expansion and Training - The company aims to train about 1,000 injection doctors by the end of 2024, primarily targeting first-tier and leading second-tier cities [6] - The sales strategy will focus on direct client institutions, light medical aesthetic institutions, and certain channel institutions [6] Group 4: Production and Cost Considerations - Currently, there are no plans to establish domestic production facilities, although local production could reduce costs [7] - The company acknowledges the uncertainty in future sales and advises investors to be cautious [7] Group 5: Regulatory and Market Challenges - The registration process for AestheFill took approximately 1.5 years, which is considered normal in the industry [9] - The company faced challenges regarding the safety of PDLLA, which have been alleviated following product approval [9] Group 6: Future Product Development - HARA hyaluronic acid is currently in clinical trials, with registration expected by the end of the year [10] - The company plans to promote hyaluronic acid in conjunction with AestheFill, with a focus on collagen products as a key future offering [11] Group 7: Financial Planning and Risk Management - The new pharmaceutical base is under construction, funded by internal resources and bank loans [12] - The company emphasizes the uncertainty surrounding AestheFill's market launch and sales, urging investors to pay attention to related announcements [12]